Canada-U.S. syndicate back Milestone Pharma’s oral drug for cardiac arrhythmia
Making the Milestone
The venture arm of the Business Development Bank of Canada helped lead a C$13 million ($13.3 million) series A round last week in cardiovascular play Milestone Pharmaceuticals Inc. The financing is intended to help develop an oral candidate to treat a form of cardiac arrhythmia.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.